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Protection from toxicant-mediated renal injury in the rat with exposure to cisplatin: direct toxicity of the agent on tubu-
anti-CD54 antibody. lar cells [2], vascular factors [3, 4], reactive oxygen species
Background. The benefit of the potent chemotherapeutic [5], and inflammatory cells [2]. We sought to investigateagent cisplatin in treating neoplasms is limited by nephrotoxic-
the role of the adhesion receptor CD54 [intercellularity. We tested the hypothesis that CD54 [intercellular adhesion
adhesion molecule-1 (ICAM-1)] in an animal model ofmolecule-1 (ICAM-1)] is an important mediator in cisplatin-
mediated renal failure. cisplatin-mediated nephropathy.
Methods. The effect of a monoclonal anti-CD54 antibody Adhesion receptors mediate leukocyte adhesion to
was evaluated in a rat model of cisplatin toxicity. Renal func- other leukocytes, endothelial cells, and cell matrix com-tion, histopathology, renal myeloperoxidase activity, and mor-
ponents, and are thought to be important in the local-tality were determined in the anti-CD54 and placebo groups.
ization of white cells to sites of inflammation. CD54Results. Renal CD54 mRNA expression was markedly in-
creased by 24 hours after exposure to cisplatin in mice. An (ICAM-1) is a member of the immunoglobulin super-
improvement in renal function, mortality, and histological ab- family. It is expressed on vascular endothelium, and its
normalities was evident in animals exposed to cisplatin and expression is regulated by stimuli such as interleukin-1treated with anti-CD54 antibody (mAb). Seven days after the
and tumor necrosis factor-a. CD54 serves as a ligandadministration of cisplatin, the mean creatinine was 0.65 6
for the b2 integrins, LFA-1 (CD11a/CD18) and Mac-10.05 mg/dl in the rats that received anti-CD54 mAb and 4.76 6
1.42 in control animals (P , 0.02). Mortality was lower in (CD11b/CD18), on leukocytes. To evaluate the possible
experimental animals (0 vs. 29% in control rats seven days role of CD54 in cisplatin nephropathy, we administered
following cisplatin, P , 0.04). Histological evidence of cell a monoclonal antibody (mAb) against CD54 to rats ex-injury was markedly attenuated (P , 0.04) in the treated com-
posed to cisplatin.pared with the control rats.
Conclusion. CD54 may be critical in the pathophysiology
of renal injury following cisplatin, perhaps by its effects on
METHODSleukocyte–endothelial interactions.
Animal protocols
All animal experimentation was conducted in confor-
The potent antineoplastic agent cisplatin (cis-diam- mity with the “Guiding Principles for Research Involving
minedichloroplatinum II) is among the most commonly Animals and Human Beings.” Male Sprague-Dawley
used drugs in the therapy of cancer and has markedly rats weighing 180 to 240 g and male Swiss Webster mice
improved the prognosis of patients with germ cell and weighing 20 to 25 g (Charles River Breeding Labora-
other tumors. Nephrotoxicity is frequent and is the major tories, Wilmington, MA, USA) were allowed free access
limitation to the use of cisplatin [1]. Several mechanisms to standard rodent chow and water. The animals were
are believed to contribute to renal dysfunction following anesthetized with an intraperitoneal injection of sodium
pentobarbital (65 mg/kg). The animals were placed on
a homeothermic table to maintain the core body temper-Key words: nephrotoxicity, acute renal failure, intercellular adhesion
molecule-1, adhesion receptors, cisplatin toxicity, leukocyte. ature at approximately 378C during the period of anes-
thesia. Anti-CD54 mAb (IgG1; IA29 [6]), placebo (5 mg/Received for publication June 30, 1998
kg bovine serum albumin; Sigma Chemical Co., St. Louis,and in revised form March 30, 1999
Accepted for publication April 12, 1999 MO, USA), control antibody (IgG1 antimonkey CD3),
or vehicle (0.9% NaCl) alone was administered via the 1999 by the International Society of Nephrology
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Table 1. Experimental groups Hybridization was carried out in formamide at 428C, and
the blots were washed in 2 3 SSPE [SSPE 5 (in mm)Time of
Group Treatment administrationa 150 NaCl, 10 NaH2PO4, 1.0 ethylenediaminetetraacetic
I Placebo 0 hours acid (EDTA)] at room temperature twice, 2 3 SSPE at
II Anti-CD54 mAb 0 hours 658C twice, and then 0.5 3 SSPE twice at room tempera-
III Placebo 0, 8 and 24 hours
ture. Autoradiograph densities were compared using Ko-IV Anti-CD54 mAb 0, 8 and 24 hours
V Placebo 22 hours dak digital science image analysis software 2.0.2 (East-
VI Anti-CD54 mAb 22 hours man Kodak Company, Rochester, NY, USA).
VII Placebo 1 hour
VIII Anti-CD54 mAb 1 hour
Monoclonal antibodies
a Times are relative to the time of administration of cisplatin (0 hours)
Cell culture supernatant or mouse ascitic fluid from
hybridoma cell lines producing mouse IgG1 anti-rat
CD54 (anti–ICAM-1) mAb (IA29) [6] was filtered prior
to injection. The adhesion of activated (but not resting)tail vein in a total volume of 500 ml. In some experiments,
the placebo consisted of 500 ml of ascites from an animal lymphocytes to the cultured high endothelial cell line,
Ax, is inhibited by 1A29 antibodies [6]. This antibodyinjected with incomplete Freund’s adjuvant (Sigma Chem-
ical Co.) but no hybridoma cells. Experiments performed has also been shown to inhibit phorbol 12-myristate 13-
acetate–induced aggregation of rat phytohemagglutininwith bovine serum albumin, the ascites placebo, and ve-
hicle (0.9% NaCl) yielded equivalent results; thus, the blasts in vitro [6]. In rats, Sasso et al found 28.3 6 4.1%
of injected indium-111–labeled 1A29 present in theresults were combined. Cisplatin (Sigma) was adminis-
tered intraperitoneally at a dose of 7.5 mg/kg. Blood blood at 15 minutes [9]. This decreased to 8.5 6 0.9%
at 18 hours. At 15 minutes, 5.0 6 0.2% of the injectedsamples for blood urea nitrogen (BUN) and creatinine
determination were obtained from the tail vein or via antibody was found in the kidney and at 18 hours 6.7 6
0.2% was localized in the kidney [9]. The placebo con-cardiac puncture at baseline and at several time points
(Figures 1–9) following the administration of cisplatin. sisted of an equivalent volume (500 ml) and protein con-
centration of bovine serum albumin (Sigma) or ascitesSome animals were sacrificed at predetermined time
points in order to obtain tissue for histopathology and from an animal injected with incomplete Freund’s adju-
vant (Sigma) but no hybridoma cells. Ascitic fluid con-determination of myeloperoxidase (MPO) activity. All
experiments were blinded, that is, the investigator ad- taining the irrelevant control antibody (anti-monkey
CD3) was the generous gift of Drs. Paul Russel and A.B.ministering the mAb was not aware of the identity of
the substance administered to each animal until all of Cosimi (Massachusetts General Hospital, Boston, MA,
USA).the results were obtained.
Experimental groups Light microscopy
At 4 hours or 3, 4, or 7 days following cisplatin admin-Animals in group I received placebo, vehicle, or con-
trol antibody immediately prior to cisplatin (Table 1). istration, rat kidneys were removed from animals anes-
thetized with pentobarbital (100 mg/kg) and were forma-Those in group II received anti-CD54 mAb immediately
prior to the administration of cisplatin. Group III re- lin fixed, paraffin embedded, sectioned at 4 microns, and
stained using hematoxylin and eosin and periodic acid-ceived three doses of placebo. The initial dose was ad-
ministered immediately prior to cisplatin, and subse- Schiff stains. The percentage of tubules in the outer
medulla that showed epithelial necrosis with luminal ne-quent doses were given 8 and 24 hours later. Group IV
received three doses of anti-CD54 mAb administered at crotic debris and tubular dilation was each quantitated
as follows: 0 5 none, 11 5 ,10%, 21 5 10 to 25%,the same time points. Group V received one dose of
placebo two hours prior to cisplatin. Group VI received 31 5 26 to 75%, 41 5 .75%. The extent of infiltration
of the outer medulla by inflammatory cells was gradedone dose of anti-CD54 mAb two hours prior to cisplatin.
Group VII received one dose of placebo one hour after similarly. The estimates were performed on coded sec-
tions without the knowledge of the experimental groupthe administration of cisplatin. Group VIII received one
dose of anti-CD54 one hour after cisplatin. to which the animals belonged.
Myeloperoxidase activityNorthern analysis
Total mRNA was prepared, and blots were probed Myeloperoxidase activity, used as an indicator of neu-
trophil infiltration [10], was measured in coded kidneywith 32P-labeled full-length mouse CD54 cDNA [7] using
standard techniques [8]. Briefly, kidney tissue was ho- homogenates four days after cisplatin administration.
Aliquots (0.2 ml) of 40,000 3 g supernatants of kidneymogenized in guanidine isothiocyanate, and RNA was
isolated by centrifugation in a cesium chloride gradient. homogenates, prepared as previously described [11],
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were added to 0.8 ml of reaction mixture containing 60
mm potassium phosphate buffer, pH 6.0, 0.20 mg/ml
o-dianisidine dihydrochloride (Sigma), and 0.0006%
H2O2. The change in absorbance was measured at 460
nm. MPO activity was normalized to the protein content
of the supernatant [11] and was expressed as the percent-
age increase over animals subjected to sham surgery.
Fractional excretion of sodium
Serum and urine sodium were measured using a flame
photometer (Instrumentation Laboratory, Lexington,
MA, USA), and fractional excretion of sodium (FENa)
was calculated as: (UrineNa 3 SerumBUN/UrineBUN 3 Se-
rumNa) 3 100.
Statistics
Creatinine and BUN values are expressed as means 6
1 se. Analysis of variance was used to determine if differ-
ences among mean values of BUN, creatinine, and MPO
levels reached statistical significance. Student’s t-test was
used for comparisons between groups. Fisher’s exact test
was used to determine if differences in mortality, histo-
logical parameters, autoradiographic densities, and FENa
were significant. Mortality rates were calculated for the
seven days following reversal of anesthesia. Animals sac-
rificed before seven days [for histological specimens,
MPO activity, or Northern analysis] were not included
in mortality statistics. A P value ,0.05 was considered
significant.
RESULTS
Effect of cisplatin on CD54 mRNA expression
In normal mice, renal CD54 mRNA levels were ele-
vated at 24 hours after exposure to cisplatin (7.5 mg/ Fig. 1. Effect of cisplatin on renal CD54 mRNA expression. Northern
analysis demonstrates increased CD54 mRNA expression in normalkg) when compared with levels in kidneys from sham-
kidney tissue 4 and 24 hours following exposure to cisplatin. Littleinjected animals (Fig. 1). Quantitation demonstrated that
CD54 mRNA is detected following an injection of placebo. A represen-
CD54 mRNA (normalized to GAPDH mRNA) was in- tative blot is shown in (A). Hybridization with a full-length human
GAPDH probe was used to demonstrate equal loading of lanes. Quanti-creased to twofold levels in vehicle-treated animals at
tation of ICAM-1 mRNA expression (normalized to GAPDH mRNA)four hours (P 5 NS) and 2.3-fold at 24 hours (P , 0.02;
is presented (B). Symbols are: ( ) cisplatin; ( ) placebo; *P , 0.02.
Fig. 1B).
Effect of anti-CD54 monoclonal antibody on renal
function following cisplatin administration pattern of protection is seen when urea nitrogen values
are examined (Fig. 3).In placebo-treated animals, serum creatinine in-
creased approximately fourfold over baseline three days
Effect of different dosing regimens of anti-CD54following the administration of cisplatin (7.5 mg/kg; Fig.
monoclonal antibody on renal function following2). The mean creatinine levels increased further to ap-
cisplatin administrationproximately 10-fold baseline by seven days after cis-
platin. Creatinine levels from three to seven days follow- Rats that received multiple doses of anti-CD54 mAb
(group IV) were also protected from renal dysfunctioning the induction of nephropathy were significantly lower
(P , 0.05) following cisplatin in animals (group II) (P , 0.01) when compared with rats receiving placebo
(group III; Fig. 4). A single dose of anti-CD54 mAbtreated with anti-CD54 mAb at the time of administra-
tion of cisplatin when compared with the mean creatinine given two hours prior (group VI) to the administration
of cisplatin resulted in protection from renal dysfunctionlevels in rats receiving placebo (group I; Fig. 2). A similar
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Fig. 2. Effect of treatment with anti-CD54 monoclonal antibody
(mAb) on renal function as measured by serum creatinine following Fig. 4. Effect of different treatment regimens on renal function follow-
cisplatin administration. Creatinine values were measured prior to cis- ing cisplatin administration. Creatinine values prior to cisplatin and on
platin and daily from days 1 through 7 following cisplatin administration. days 1 through 9 following induction of nephropathy are presented.
Symbols are: (h) anti-CD54; (j) placebo; ( ) control antibody; *P , Animals received three doses of anti-CD54 monoclonal antibody ( ;
0.05; **P , 0.01; ***P , 0.0002. In Figures 2, 3, 4, 5, 6, and 9, data group IV) or placebo (j; group III) at the time of cisplatin administra-
are expressed as means 6 1 sem. Numbers in parentheses represent tion and 8 and 24 hours after cisplatin injection. P values are **P ,
the number of animals studied at each point. P values for comparisons 0.01 and ***P , 0.002 for the comparison of anti-CD54 mAb and
between anti-CD54 mAb (group II) and placebo-treated (group I) placebo-treated groups. In addition, mean creatinine values on days 4,
animals are presented. 5, and 6 in the group receiving three doses of anti-CD54 mAb were
significantly lower (P , 0.03) that the values in animals following a
single dose of mAb.
that was no different than in animals treated with anti-
CD54 at the time of cisplatin (Fig. 5). The administration
of anti-CD54 mAb (group VIII) after the exposure to
cisplatin did not result in protection from renal failure.
The mean serum creatinine in group VIII was no differ-
ent than that in the placebo group (VII) on days 0
through 7 following the administration of cisplatin
(Fig. 6).
Mortality following cisplatin administration and
treatment with anti-CD54 monoclonal
antibody or placebo
Another indication of the protection against toxic ne-
phropathy in the treated animals was reflected in the
mortality rates (Table 2). None (0%) of the anti-CD54–
treated rats (group II, N 5 13) followed for seven days
after cisplatin expired, whereas four (29%) of the control
post-cisplatin (group I, N 5 14) animals died (P , 0.04).
Fig. 3. Effect of treatment with anti-CD54 monoclonal antibody Effects of anti-CD54 monoclonal antibody on
(mAb) on renal function as measured by serum urea nitrogen following histological changes of cisplatin nephropathycisplatin administration. Serum urea nitrogen values were measured
prior to the induction of nephropathy and daily from days 1 through Histological examination of kidney sections three,
7 after cisplatin. Symbols are: (h) anti-CD54; (j) placebo; *P , 0.05; four, and seven days following cisplatin administration**P , 0.01; ***P , 0.0002.
revealed decreased tubular necrosis in kidneys from anti-
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Table 2. Mortality ratesa
Number of
Experimental group Mortality animals
Placebo (group I) 4 (29%) 14
Anti-CD54 mAb (group II) 0 (0%)b 13
a Only animals followed for 7 days following exposure to cisplatin are included
in the mortality statistics
b P , 0.04 vs. placebo
were present in the kidneys from animals treated with
anti–CD54 compared with the placebo group on day 4
(P , 0.05). Given the increases in the CD54 mRNA level
observed after exposure to cisplatin (Fig. 1), histological
sections were examined four hours after the administra-
tion of cisplatin. No morphological differences in the
kidneys from the anti-CD54 and placebo groups were
observed. At four hours, there were no differences be-
tween mean serum urea nitrogen, creatinine, or FENa in
Fig. 5. Effect of administration of anti-CD54 monoclonal antibody the anti-CD54 and placebo-treated animals (data not
(mAb) prior to cisplatin administration on renal function. Creatinine
shown).values zero to seven days following cisplatin are presented. Symbols
are: (j) placebo; ( ) anti-CD54; **P , 0.01; ***P , 0.002.
Effect of anti-CD54 monoclonal antibody on
myeloperoxidase activity in cisplatin nephropathy
Myeloperoxidase activity, determined as an index of
tissue neutrophil content [10], was increased over levels
in kidneys from sham-injected animals by 24 hours fol-
lowing the exposure to cisplatin. MPO activity was sig-
nificantly lower at 48 (P , 0.05) and 72 (P , 0.01) hours
in animals treated with anti-CD54 mAb (group II) than
in those treated with placebo (group I; Fig. 8).
Effect of anti-CD54 monoclonal antibody on the
fractional excretion of sodium in cisplatin nephropathy
Fractional excretion of sodium (FENa) was increased
at three days following the administration of cisplatin
(P , 0.01 vs. day 1), but there was no difference between
the mean FENa in the anti-CD54 and placebo-treated
groups (Fig. 9).
DISCUSSION
Acute renal failure is a common clinical entity that
most often results from ischemia/reperfusion injury
Fig. 6. Effect of administration of anti-CD54 monoclonal antibody and/or exposure to toxicants. Both exposure to cisplatin(mAb) after cisplatin on renal function. Mean creatinine values prior
and ischemia/reperfusion produce acute tubular necrosisto cisplatin and on days 1 through 7 after the administration of anti-
CD54 ( ) or placebo (j) and cisplatin are shown. No statistically histologically. Alterations in the expression of several
significant differences were observed between the groups at any of the genes are also similar in the two conditions [12]. Cisplatintime points evaluated.
nephrotoxicity may be due to the induction of ischemia
by the drug [13]. Because CD54 appears to be involved
in the pathogenesis of ischemic acute renal failure [14],
we sought evidence for its involvement in cisplatin-medi-CD54 mAb-treated animals (group II) as compared with
ated renal injury.the control rats (group I) at the early time point (days
The introduction of cisplatin approximately 25 years3 and 4) and decreased dilation of tubules on day 7
(Table 3 and Fig. 7, P , 0.04). Fewer inflammatory cells ago markedly improved the prognosis of patients with
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Table 3. Histopathology following cisplatin
Day 3 and day 4 Day 7
Anti-CD54 Placebo Anti-CD54 Placebo
Outer medullary ,25% 13 12 9 6
tubular necrosis $25% 3 13 2 2
P value 0.033 0.72
Outer medullary ,25% 14 19 5 0
tubular dilation $25% 2 6 6 8
P value 0.36 0.026
The percent of tubules in the outer medulla that showed epithelial necrosis or tubular dilation was quantified on coded sections. The numbers shown represent
the number of animals with kidney sections in each category.
germ cell and other tumors [15]. The major limitation Renal vasoconstriction may be critical in the induction
to the use of this agent is nephrotoxicity. Alterations in of nephrotoxicity by cisplatin. In cancer patients, pro-
renal function occur commonly with doses in excess of gressive decreases in effective renal plasma flow have
5 mg/kg [2, 16] and can contribute to mortality [17]. One been demonstrated during an infusion of cisplatin and
dose of cisplatin may result in acute renal failure [18], prior to any alteration in the glomerular filtration rate
and multiple doses can cause chronic impairment of renal (GFR) [13]. Decreased renal blood flow (RBF) has been
function. In early clinical trials, azotemia occurred in demonstrated in dogs [26] and rats [4] 48 to 72 hours
approximately 25% of patients after a single dose of after cisplatin administration. Improvement in GFR
cisplatin [19]. after volume expansion parallels the increase in RBF,
Direct toxicity to renal tubular epithelial cells and suggesting that vasoconstriction is an important determi-
hemodynamic alterations are thought to contribute to nant of renal function following exposure to cisplatin [2].
renal dysfunction following exposure to cisplatin [2, 3, The nitric oxide synthase inhibitor NG-nitro-l-arginine
20]. Cisplatin induces DNA cross-links, which result in methyl ester inhibits the ability of glycine to protect
the inhibition of DNA synthesis and correlate with toxic- against cisplatin-mediated nephrotoxicity in rats, again
ity, although the precise relationship to nephrotoxicity suggesting the importance of hemodynamic factors [27].
is unknown [2]. Within the kidney, platinum is concen- Other investigators have argued that RBF is not mark-
trated largely in the renal cortex and is found in both edly decreased immediately after cisplatin administra-
the cytoplasm and subcellular organelles. Ten minutes tion and thus suggest that an alteration in RBF is not a
after an injection of cisplatin in rats, it is found primarily primary mechanism of cisplatin-mediated nephrotoxicity
in the juxtamedullary and outer stripe regions of the [28].
kidney, with the highest concentration in the S3 segments Other mechanisms may contribute to renal dysfunc-
of the proximal tubule [2]. tion following exposure to cisplatin. The drug results in
Lam and Adelstein found tubular cell casts or tubular decreased mitochondrial respiratory function, respira-
epithelial cells in 100% of 47 urine specimens from pa- tory chain enzyme activity, and glutathione peroxidase
tients two to four days after treatment with cisplatin [21].
in rat kidneys, possibly resulting in free radical-mediated
In animals treated with cisplatin, patchy necrosis of cells
renal injury [29]. Cisplatin may also decrease the synthe-in the medulla with cellular debris in tubular lumens and
sis or release of vasopressin [30]. It has been postulateddilated tubules has been described [22]. Impairment of
that the nephrotoxic effects of cisplatin can be attributedproximal tubular function has been observed immedi-
to its affinity for sulfhydryl groups of enzymes. Glutathi-ately after administration of the drug to dogs [15]. In
one, a sulfhydryl-containing compound, may protectpatients, both decreased proximal absorption of sodium
against cisplatin-induced renal dysfunction [31]. Cis-and water and increased excretion of the tubular marker
platin increases lipid peroxidation [31] and may alterN-acetyl-b-D-glucosamidase (NAG) have been ob-
prostaglandin synthesis or metabolism [2]. Calcium hasserved [23]. However, significant decreases in renal func-
been implicated in cisplatin nephrotoxicity by investiga-tion do not occur until several days after cisplatin admin-
tors who have found increases in renal calcium contentistration, suggesting that factors other than tubular cell
and endoplasmic reticulum calcium pump activity priordamage may be important in the development and per-
to morphological evidence of injury following the admin-haps the initiation of nephrotoxicity. Although CD54
istration of cisplatin [32]. In addition, calcium channelcan be induced on renal tubular epithelial cells following
blockers may provide protection from cisplatin-mediatedinjury [24, 25], the data demonstrating no difference in
injury [33]. Increased Na1,K1-ATPase activity with ATPFENa between the anti-CD54 and placebo-treated groups
depletion has also been implicated in cisplatin nephro-support another mechanism of protection with anti-
CD54 in cisplatin nephropathy. toxicity [34].
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Fig. 9. Effect of anti-CD54 monoclonal antibody (mAb) on fractional
Fig. 8. Effect of anti-CD54 monoclonal antibody (mAb) on myeloper- excretion of sodium following exposure to cisplatin. Fractional excretion
oxidase activity in cisplatin nephropathy. Myeloperoxidase (MPO) ac- of sodium (FENa) was determined on days 1, 3, and 7 following cisplatin
tivity was measured in kidney tissue 24, 48, or 72 hours following and anti-CD54 (h) or placebo (j). FENa is significantly higher on day
exposure to cisplatin and anti-CD54 mAb (group II) or placebo (group 3 than on day 1, but (*) no statistically significant differences in FENa
I). MPO activity is presented as a percentage of activity at the same were observed between the anti-CD54–treated and placebo groups.
time following sham-injection in normal animals. Symbols are: ( )
sham-operated; (h) anti CD54; (j) placebo; *P , 0.05 and **P , 0.01
for comparison between MPO activity in kidneys from anti-CD54 mAb
and placebo-treated rats.
agents protect against toxicity in animal models or in
vitro systems [40]. To our knowledge, no studies examin-
ing the role of adhesion receptors of cisplatin nephrotox-
The data presented demonstrate marked protection icity have been undertaken. These data provide evidence
from renal dysfunction following cisplatin with adminis- for the importance of the adhesion receptor CD54
tration of anti-CD54 mAb to rats. Although several (ICAM-1) in the functional and histological changes that
agents have recently shown promise in experimental follow the administration of cisplatin. We have shown
increases in CD54 mRNA at early time points followingmodels of toxic nephropathy, the treatment of cisplatin-
mediated nephrotoxicity clinically remains largely sup- the administration of cisplatin, before decreases in renal
function and histological evidence of injury are seen.portive.
Hydration, mannitol, and/or furosemide are nonspe- Although CD54 is expressed constitutively on the endo-
thelium in kidneys [8], we have found that administeredcific measures commonly used in patients receiving cis-
platin treatment [1], although clear protection of renal anti-CD54 mAb was localized largely to the vasa rectae
of the outer medulla in a model of ischemia/reperfusionfunction has not always been seen with these interven-
tions [15]. Sodium thiosulfate [35, 36] and metabolites [11]. This area of the kidney may be particularly suscepti-
ble to injury given its basal hypoxia [41]. These studiesof amifostine (WR-2721) may inactivate toxic platinum
species and protect against nephrotoxicity [37]. Glutathi- also support the hypothesis that neutrophils contribute
to renal dysfunction.one is also protective against cisplatin-induced nephro-
toxicity, perhaps by replacing sulfhydryl groups of en- Leukocytes may cause renal dysfunction via several
mechanisms. Following activation, polymorphonuclearzymes that have reacted with cisplatin [38]. Probenecid
inhibits cisplatin secretion in renal tubules and has been neutrophils release many potentially destructive media-
tors (including reactive oxygen species, cytokines, prote-shown to be protective in a phase I trial [39]. Other
b
Fig. 7. Effects of anti-CD54 monoclonal antibody (mAb) on histopathology in toxic nephropathy. Light microscopy of a representative section
of kidney outer medulla four days after cisplatin administration (a) demonstrates extensive tubular epithelial cell necrosis and mitosis (arrow) in
the control animal (group I). A comparable section from the kidney of an anti-CD54 mAb (group II)-treated rat (b) shows histologically normal
tubules. Sections four hours after the administration of cisplatin and placebo (c) or anti-CD54 mAb (d) show little evidence of injury (hematoxylin
and eosin 3200).
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